Supergen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Withdrawal of NDA for second-line treatment of pancreatic cancer is “most prudent course of action,” firm says following talks last week with FDA. Supergen is moving ahead with a combination trial with gemcitabine.
You may also be interested in...
SuperGen Orathecin Hits Road Block: Phase III Nixed For Combo Claim In Pancreatic Cancer
Phase II trial fails to meet pre-specified threshold for median survival.
SuperGen Orathecin Hits Road Block: Phase III Nixed For Combo Claim In Pancreatic Cancer
Phase II trial fails to meet pre-specified threshold for median survival.
SuperGen Withdraws Orathecin From EMEA Consideration
The European Medicines Agency raises “major concerns” with the pancreatic cancer therapy rubitecan.